Lifeward Ltd. Financial Performance Review
Lifeward Ltd. (NASDAQ: LFWD) has seen impressive growth in its financial results for the fourth quarter and the full year of 2024, with total revenues hitting a record of $25.7 million, marking an 85% increase compared to the previous year. This growth reflects Lifeward's strong commitment to innovating medical technology aimed at improving the lives of individuals with physical limitations.
Key Highlights and Milestones
Among the standout achievements in 2024, Lifeward's sales of the ReWalk Personal Exoskeleton soared by 130%, largely attributed to the recent establishment of Medicare coverage for these devices. The expansion of sales demonstrates Lifeward's efficacy in addressing the needs of users, which continues to foster a resilient pipeline of qualified leads, currently exceeding 110 potential sales opportunities within the U.S.
The company launched its 2025 Sustainable Growth Plan, aimed at balancing revenue growth with cost reduction strategies to enhance profitability. This plan is designed to streamline operations while still investing in the development of core product lines.
Operational Adjustments and Partnerships
Lifeward has rightfully streamlined its operations in the U.S. by closing two facilities, achieving a cumulative staff reduction of 35% since acquiring AlterG. This operational efficiency is crucial as it allows for better allocation of resources towards areas that drive revenue, such as the partnership with CorLife. This collaboration is set to expand Lifeward's reach into the workers' compensation market, enhancing distribution for the ReWalk personal exoskeleton.
2025 Financial Outlook
Looking forward, Lifeward projects full-year revenues for 2025 to be between $28 million and $30 million, with anticipated adjusted gross margins of 47% to 49%. The company also expects to reduce non-GAAP operating expenses to a range between $22 million and $23 million, leading to an operating loss anticipated between $7 million and $9 million. The first quarter is projected to reflect the lowest revenue volume due to seasonal trends, but Lifeward foresees continuous growth during the latter quarters of the year.
Revenue Breakdown and Future Projections
For the fourth quarter of 2024, Lifeward generated $7.5 million in revenue, a 10% increase from $6.9 million in Q4 2023. Notably, sales from ReWalk systems and associated products contributed $2.0 million but experienced a marginal decline of 6% when juxtaposed with last year. Contrarily, the sale of AlterG products witnessed a robust $5.5 million, up 17% from the previous year.
Despite operational loss spikes, which reached $15.2 million in the fourth quarter, compared to $6.1 million during the same quarter in the previous year, Lifeward has acknowledged a decrease in adjusted operating loss, showcasing a resilient performance amid challenges.
Strategic Aims and Market Expansion
As Lifeward ventures into the new financial year, the focus will be on refining operational efficiency while scaling revenue generation. The company aims to capitalize on its innovative product portfolio, including the ReWalk Exoskeleton and MyoCycle systems, to further improve accessibility for users globally.
Chief Executive Officer, Larry Jasinski, expressed confidence in the company's strategic direction, asserting that Lifeward is determined to become a profitable entity while remaining committed to transforming rehabilitation and recovery through cutting-edge medical technologies.
Frequently Asked Questions
What is the key achievement for Lifeward in 2024?
Lifeward achieved record annual revenue of $25.7 million, marking an 85% increase from the prior year.
How much did the ReWalk personal exoskeleton sales increase?
Sales of the ReWalk personal exoskeleton surged by 130% in 2024 due to new Medicare coverage.
What are Lifeward's financial projections for 2025?
Lifeward expects full-year revenues to be between $28 million and $30 million with projected adjusted gross margins of 47% to 49%.
What operational changes has Lifeward implemented?
Lifeward streamlined operations, closing two U.S. facilities and reducing headcount by 35% since the AlterG acquisition.
How did Lifeward's Q4 2024 revenue compare to last year?
In Q4 2024, Lifeward reported revenue of $7.5 million, up 10% from $6.9 million in Q4 2023.
